Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 3.2000 (-1.54%)
GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 55.19 (+1.77%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 55.19 (+1.77%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Grant funding awarded to support lupus-focused community programs across the United States

GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 244.44 (+0.80%)
LLY : 919.77 (+3.74%)
ABBV : 217.49 (+2.05%)
GSK : 55.19 (+1.77%)
CSLLY : 24.5500 (+2.21%)
PFE : 28.08 (+1.12%)
SNY : 48.18 (+3.12%)
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...

GSK.LN : 2,064.000 (+0.05%)
GSK : 55.19 (+1.77%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 105.40 (+5.54%)
KPTI : 5.57 (+5.09%)
GTBP : 0.4081 (-1.50%)
GSK : 55.19 (+1.77%)
TAK : 18.52 (+1.37%)

Barchart Exclusives

Ignore the Panic and Buy the Dip in Micron Stock, Says Bank of America
A sharp pullback in Micron stock tied to AI efficiency fears may be creating a compelling entry point as demand fundamentals remain intact. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.